HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short

Hims & Hers Health stock rose after FDA advisory panel backed four peptides for compounded GLP-1 drugs.

Leerink Partners estimates a $2.2 billion peptide market, with Hims potentially capturing 20% share.

Martin Shkreli has taken a short position on HIMS stock, according to the report.

The FDA panel's backing may influence regulatory decisions on compounded semaglutide alternatives.

Hims plans to offer compounded versions of popular weight-loss and diabetes drugs.